Janel Johnson Ph.D.
New York, New York, United States of
America
25 Years Experience
Molecular Geneticist experienced in
Neuroscience, Oncology, Immunology, and
Intellectual Property
Education
University College London
Ph.D., Molecular
Neuroscience
University College London
M.Phil, Molecular Genetics
Research Expertise
Genetics
Neurodegeneration
Amyotrophic Lateral Sclerosis
Frontotemporal Demetia
Next Generation Sequencing
About
Dr. Janel Johnson is a distinguished
Biologist with over 20 years of
dedicated academic research focused on
the genetics of Neuroscience,
Oncology, and Immunology. She obtained
her BA in Biology from The Johns
Hopkins University in 1999, following
which she conducted groundbreaking
research at The Johns Hopkins
University Sidney Kimmel Cancer
Center. Here, she explored the
selective cytotoxic effects of a
tyrosine kinase inhibitor in a
transgenic mouse model of acute
myeloid leukemia. Transitioning to The
National Institutes of Health (NIH),
Dr. Johnson continued her impactful
career, making significant
contributions to the study of
Alzheimer’s disease and Parkinson's
disease genetics. Sponsored by the
NIH, she pursued her MPhil and PhD in
Molecular Genetics at University
College London, focusing on unraveling
the genetic basis of Spinocerebellar
Ataxia (SCA) and Childhood Motor
Neuron Disease. Notably, her research
elucidated that mutations in the Tau
Tubulin Kinase 2 gene cause SCA Type
11, and she identified riboflavin
transporter mutations as the
underlying cause of Childhood Motor
Neuron Disease, highlighting the
potential for vitamin B2
supplementation as a therapeutic
intervention. Furthering her
postgraduate research at NIH, Dr.
Johnson delved into investigating the
genetics of Amyotrophic Lateral
Sclerosis (ALS) and related motor
neuron disorders. Her seminal findings
uncovered that mutations in genes such
as Valosin Containing Protein,
Matrin-3, and a serine
palmitoyltransferase subunit
contribute to the pathogenesis of ALS,
shedding light on overlapping pathways
and pleiotropic effects on other
diseases. In addition to her extensive
research endeavors, Dr. Johnson has
made significant strides in HIV
research at the Walter Reed Army
Institute of Research, utilizing novel
multiomics technologies to investigate
interactions between the retrovirus
and host cells. Her recent experience
in immunology includes serving as a
Patent Examiner for the United States
Patent and Trademark Office, where she
evaluated inventions for cancer
immunotherapy. Dr. Johnson is widely
recognized in the field of molecular
genetics for her expertise and
numerous scientific breakthroughs,
contributing significantly to our
understanding of complex disorders.
She is deeply passionate about
research and serves as a vocal
advocate for diversity, equity, and
inclusion (DEI) in science and
healthcare. Dr. Johnson's exceptional
talent lies in her ability to
effectively communicate scientific
concepts to both experts and the
general public. Her lifelong
commitment is to achieve DEI for
genetic populations that have been
traditionally understudied.